Сравнение

Cerebrolysin vs. Glepaglutide

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

96889-70-6

нет данных

Молекулярная масса

нет данных

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Cerebrolysin

Cerebrolysin is a mixture of low-molecular-weight peptides (predominantly below 10 kDa) and free amino acids obtained by enzymatic cleavage of lipid-free porcine brain proteins. The manufacturer and preclinical literature describe a neurotrophic and neuroprotective mode of action said to mimic endogenous neurotrophic factors; cell and animal models have reported effects on neuronal survival, synaptogenesis and anti-apoptotic signalling (including PI3K/Akt). Because it is a complex, incompletely characterised mixture, the precise mechanism in humans remains unclear.

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Cerebrolysin	Glepaglutide
Австрия	Рецептурный	—
CN	Рецептурный	—
Германия	Неясно	Не одобрено
RU	Рецептурный	—
США	Не одобрено	Не одобрено

Полные записи

Frequently asked questions

What is the difference between Cerebrolysin and Glepaglutide?: Cerebrolysin is classified as "Исследования (прочее)", while Glepaglutide is classified as "Исследования (прочее)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cerebrolysin or Glepaglutide?: The highest available evidence level is "РКИ на людях" for Cerebrolysin and "РКИ на людях" for Glepaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cerebrolysin and Glepaglutide in Germany and the United States?: Германия: Cerebrolysin — Неясно, Glepaglutide — Не одобрено. США: Cerebrolysin — Не одобрено, Glepaglutide — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Cerebrolysin

Glepaglutide

Австрия

Рецептурный

—

Рецептурный

—

Германия

Неясно

Не одобрено

Рецептурный

—

США

Не одобрено

Frequently asked questions

What is the difference between Cerebrolysin and Glepaglutide?

Cerebrolysin is classified as "Исследования (прочее)", while Glepaglutide is classified as "Исследования (прочее)". Cerebrolysin: Cerebrolysin (FPF-1070) is not a single peptide but a porcine-brain-derived preparation of low-molecular-weight peptides and free amino acids, produced by standardised enzymatic proteolysis. It is approved in several countries (including Austria, Russia and parts of Asia) for stroke, dementia and traumatic brain injury, but is not FDA-approved in the United States and not centrally approved by the EMA. Its efficacy is contested: Cochrane systematic reviews found no convincing benefit and flagged possible harm signals. Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cerebrolysin or Glepaglutide?

The highest available evidence level is "РКИ на людях" for Cerebrolysin and "РКИ на людях" for Glepaglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cerebrolysin and Glepaglutide in Germany and the United States?

Германия: Cerebrolysin — Неясно, Glepaglutide — Не одобрено. США: Cerebrolysin — Не одобрено, Glepaglutide — Не одобрено. These are factual summaries with source and review date on the individual pages.